KF13218 is a potent and long-acting selective thromboxane B2 (TXB2) synthase inhibitor used to suppress thromboxane production in human and bovine platelets; it demonstrates sustained inhibition of thromboxane synthase in platelets even after removal of the extracellular compound; in vivo, it dose-dependently inhibits serum thromboxane B2 production in rats for up to 72 hours and prevents sodium arachidonate-induced mortality in rabbits at an oral dose of 0.1 mg/kg.